Source MS Register: We understand that you might be feeling worried about the Coronavirus(COVID-19) and your MS. We have put this page together as an information resource, it will be updated with new information as appropriate.
Following the latest updates on coronavirus, the Management and Trustees have taken the difficult decision to close the Centre for all services from Monday 16th March. We hope this action will help to reduce the risk of infection, especially within our BMSTC community.
Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found.
Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show.
Source MS Society: This week the European Medicines Agency (EMA) granted a license for siponimod (brand name Mayzent) to treat adults with secondary progressive MS with active disease.
Source Winter Sports Travel: Making Travel Accessible. Winter sports are becoming more accessible than ever before. But finding the right place or activity when you're living with a challenging condition can be tough.
Try this tool to find sports and resorts in Europe that are tailored to your needs. Click here.
